Chênevert Family Brain Tumor Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 8
New Haven, CT 06511
- Chênevert Family Brain Tumor CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
Sylvia Kurz, MD, PhD
Neuro-Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Neuro-Oncology
Biography
Sylvia Kurz, MD, PhD, specializes in neuro-oncology and provides care for patients with brain tumors as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center.
An associate professor of neurology at Yale School of Medicine, Dr. Kurz's research focuses on developing new therapies and improving existing treatment protocols for brain tumors.
Dr. Kurz earned her medical and doctoral degrees from Ludwig-Maximilians-University in Germany. She completed her residency at University Hospitals Case Medical Center and a fellowship in neuro-oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital.
Titles
- Associate Professor of Neurology, Neuro-Oncology
Education & Training
- Clinical FellowMassachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School (2017)
- Research FellowDana-Farber Cancer Institute Harvard Medical School (2016)
- ResidentUniversity Hospitals Case Medical Center, Case Western Reserve University (2014)
- PhDMax-Planck-Institute for Neurobiology and Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Molecular Medicine
- InternUniversity Hospitals Case Medical Center, Case Western Reserve University (2011)
- MDLudwig-Maximilians-University, School of Medicine
Languages Spoken
- English
- Deutsch (German)
Additional Information
Board Certifications
- United Council for Neurologic Subspecialties, Neuro-Oncology (2014, recertified: 2024)
Publications
- Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.
- Cloughesy T, Allen J, Arrillaga-Romany I, Barbaro M, Batchelor T, Butowski N, Cluster A, de Groot J, Graber J, Haggiagi A, Kilburn L, Kurz S, Melemed A, Ramage S, Salacz M, Shonka N, Sumrall A, Tarapore R, Taylor L, Wen P. CTNI-54. RESPONSE BY RANO2.0 CRITERIA IN ONC201 (DORDAVIPRONE)-TREATED PATIENTS WITH RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology 2024, 26: viii109-viii109. PMCID: PMC11552873, DOI: 10.1093/neuonc/noae165.0421.
- Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.
- Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.
- Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.
- Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek H, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE). Neuro-Oncology Practice 2024, 11: 336-346. PMID: 38737615, PMCID: PMC11085831, DOI: 10.1093/nop/npae002.
- Spieker M, Rapp M, Goebel S, Karger A, Rieger D, Grosse L, Bombach P, Kurz S, Hippler M, Tatagiba M, Sabel M, Tabatabai G, Renovanz M. NCOG-32. THE SPECIFIC PSYCHOSOCIAL BURDEN OF CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS - A PROSPECTIVE STUDY. Neuro-Oncology 2023, 25: v221-v221. PMCID: PMC10639804, DOI: 10.1093/neuonc/noad179.0845.
- Kurz S, Renovanz M, Rieger J, Bombach P, Grosse L, Rieger D, Hucker S, Hille H, Hippler M, Oener O, Ruhm K, Beha J, Malek H, Moeller Y, Bitzer M, Malek N, Tabatabai G. NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS. Neuro-Oncology 2023, 25: v220-v220. PMCID: PMC10639832, DOI: 10.1093/neuonc/noad179.0842.
- Kurz S, Stammberger A, Rosahl S, Abrey L, Albert N, von Baumgarten L, Gempt J, Grosu A, Leidgens V, McLean A, Renovanz M, Schwarzenberger J, Sevenich L, Purkart T, Combs S, Tabatabai G, Hegi M, Nowosielski M. Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative. Neuro-Oncology 2023, 25: 2302-2304. PMID: 37738478, PMCID: PMC10708925, DOI: 10.1093/neuonc/noad157.
- Spieker M, Rapp M, Rieger D, Bombach P, Kurz S, Tatagiba M, Sabel M, Tabatabai G, Renovanz M. P08.03.A CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS: UNMET NEEDS AND RELEVANT PROBLEMS - A PROSPECTIVE STUDY. Neuro-Oncology 2023, 25: ii55-ii56. PMCID: PMC10489286, DOI: 10.1093/neuonc/noad137.178.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology 2023, 101: e1741-e1746. PMID: 37527941, PMCID: PMC10624483, DOI: 10.1212/wnl.0000000000207670.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma. Journal Of Clinical Oncology 2023, 41: 2079-2079. DOI: 10.1200/jco.2023.41.16_suppl.2079.
- Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.
- Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.
- de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, O'Brien B, Sloan A, Chiang V, Tatter S, Mohammadi A, Placantonakis D, Strowd R, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope K, Campian J, Kurz S, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt E. SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA. Neuro-Oncology 2022, 24: vii256-vii257. PMCID: PMC9660753, DOI: 10.1093/neuonc/noac209.989.
- Kurz S, Zan E, Cordova C, Barbaro M, Troxel A, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY. Neuro-Oncology 2022, 24: vii85-vii85. DOI: 10.1093/neuonc/noac209.322.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Forsyth P, Mandel J, Khagi S, Aiken R, Walbert T, Lieberman F, Portnow J, Battiste J, Gillespie E, Lowy I, Skolnik J. Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Journal Of Clinical Oncology 2022, 40: 2004-2004. DOI: 10.1200/jco.2022.40.16_suppl.2004.
- Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.
- Strowd R, Dunbar E, Gan H, Kurz S, Jordan J, Mandel J, Mohile N, Nevel K, Taylor J, Ullrich N, Welch M, Wasilewski A, Mrugala M. Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice 2022, 9: 91-104. PMID: 35371525, PMCID: PMC8965064, DOI: 10.1093/nop/npac002.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.
- Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.
- Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Forsyth P, Mandell J, Khagi S, Aiken R, Walbert T, Lieberman F, Portnow J, Batiste J, Carroll N, Sylvester A, Campbell P, Lowy I, Dolgoter A, Boyer J, Kraynyak K, Morrow M, McMullan T, Weiner D, Skolnik J. LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2020, 22: ii237-ii237. PMCID: PMC7678727, DOI: 10.1093/neuonc/noaa215.988.
- Liu E, Yu S, Sulman E, Kurz S. EPID-15. RACIAL AND SOCIOECONOMIC DISPARITIES DIFFERENTIALLY AFFECT OVERALL AND CAUSE-SPECIFIC SURVIVAL IN GLIOBLASTOMA. Neuro-Oncology 2020, 22: ii81-ii81. PMCID: PMC7651412, DOI: 10.1093/neuonc/noaa215.333.
- Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, de Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Taylor L, Graber J, Kilburn L, Dixit K, Lu G, Allen J, Batchelor T, Lassman A, Wen P. CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology 2020, 22: ii50-ii51. PMCID: PMC7651099, DOI: 10.1093/neuonc/noaa215.204.
- Lukas R, Chiocca E, Bush N, Landolfi J, Cavaliere R, Yu J, Kurz S, Demars N, Buck J, Hadar N, Miao J, Loewy J, Wang Y, Gelb A, Cooper L. CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology 2020, 22: ii39-ii39. PMCID: PMC7650356, DOI: 10.1093/neuonc/noaa215.162.
- Kurz S, Zan E, Gurewitz J, Cordova C, Troxel A, Sawaged Z, Sevillano-Torres H, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA. Neuro-Oncology 2020, 22: ii54-ii55. PMCID: PMC7651467, DOI: 10.1093/neuonc/noaa215.219.
- Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.
- Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.
- Cordova C, Kurz S. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports 2020, 22: 84. PMID: 32617743, DOI: 10.1007/s11912-020-00937-4.
- Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.
- Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.
- Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Karlin-Neumann G, Polsky D, Chi A. Abstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients. Clinical Cancer Research 2020, 26: a65-a65. DOI: 10.1158/1557-3265.liqbiop20-a65.
- Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.
- Kawakibi A, Tarapore R, Gardner S, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, De Groot J, Mehta M, Odia Y, Hall M, Cloughesy T, Ellingson B, Umemura Y, Allen J, Koschmann C. Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. Journal Of Clinical Oncology 2020, 38: 3617-3617. DOI: 10.1200/jco.2020.38.15_suppl.3617.
- Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, De Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Lu G, Oster W, Allen J, Batchelor T, Lassman A, Wen P. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal Of Clinical Oncology 2020, 38: 3615-3615. DOI: 10.1200/jco.2020.38.15_suppl.3615.
- Lukas R, Kurz S, Yu J, Landolfi J, Rao G, Amidei C, Buck J, Hadar N, Estupinan T, Miao J, Loewy J, Wang Y, Demars N, Gelb A, Cooper L. Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone. Journal Of Clinical Oncology 2020, 38: 2564-2564. DOI: 10.1200/jco.2020.38.15_suppl.2564.
- Kurz S, Tarapore R, Odia Y, Butowski N, Koschmann C, Aguilera D, MacDonald T, Lu G, Allen J, Oster W, Mehta M, Chi A, Wen P. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. Journal Of Clinical Oncology 2020, 38: 2563-2563. DOI: 10.1200/jco.2020.38.15_suppl.2563.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Carroll N, Bartra S, Campbell P, Bhatt K, Lowy I, Boyer J, Kraynyak K, Morrow M, McMullan T, Weiner D, Skolnik J. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal Of Clinical Oncology 2020, 38: 2514-2514. DOI: 10.1200/jco.2020.38.15_suppl.2514.
- Liu E, Kurz S, Ahn J, Sulman E. Prevalence and temporal trends of prescription drug use in cancer survivors: A population study, 2001 to 2016. Journal Of Clinical Oncology 2020, 38: 12023-12023. DOI: 10.1200/jco.2020.38.15_suppl.12023.
- Skolnik J, Reardon D, Brem S, Desai A, Bagley S, Kurz S, de la Fuente M, Nagpal S, Welch M, Sacchetta B, Bartra S, Bredlau A, Lowy I, Kraynyak K, Morrow M, McMullan T, Boyer J. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM). Journal For ImmunoTherapy Of Cancer 2020, 8: a8. DOI: 10.1136/lba2019.12.
- Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.
- Mureb M, Jain R, Poisson L, Littig I, Neto L, Wu C, Ng V, Patel S, Patel S, Serrano J, Kurz S, Cahill D, Bendszus M, von Deimling A, Placantonakis D, Golfinos J, Kickingereder P, Snuderl M, Chi A. NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology 2019, 21: vi163-vi163. PMCID: PMC6847952, DOI: 10.1093/neuonc/noz175.681.
- Patel P, Li T, Chou J, Patel A, Crispino S, Utate M, Kurz S. HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS. Neuro-Oncology 2019, 21: vi118-vi118. PMCID: PMC6846933, DOI: 10.1093/neuonc/noz175.494.
- Li T, Patel P, Chou J, Patel A, Crispo S, Utate M, Kurz S. EPID-29. THE INFLUENCE OF SOCIOECONOMIC FACTORS AND CANCER CARE RECEIVED AT DIFFERENT FACILITIES ON OUTCOME IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi80-vi81. PMCID: PMC6847338, DOI: 10.1093/neuonc/noz175.329.
- Arrillaga-Romany I, Kurz S, Sumrall A, Butowski N, Harrison R, DeGroot J, Chi A, Sulman E, Shonka N, Umemura Y, Odia Y, Mehta M, Iwamoto F, Nghiemphu P, Cloughesy T, Tarapore R, Merdinger K, Oster W, Allen J, Batchelor T, Lassman A, Wen P. ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology 2019, 21: vi20-vi21. PMCID: PMC6847973, DOI: 10.1093/neuonc/noz175.077.
- Kurz S, Silverman J, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, Zagzag D, Snuderl M, Goldberg J, S A. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi9-vi10. PMCID: PMC6847193, DOI: 10.1093/neuonc/noz175.036.
- Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Buck J, Demars N, Smith A, Miao J, Zhou J, Wang Y, Gelb A, Cooper L. ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847372, DOI: 10.1093/neuonc/noz175.018.
- Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.
- Arrillaga I, Kurz S, Sumrall A, Butowski N, Harrison R, De Groot J, Shonka N, Lieberman F, Odia Y, Tarapore R, Merdinger K, Allen J, Oster W, Mehta M, Cloughesy T, Chi A, Lassman A, Batchelor T, Wen P. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal Of Clinical Oncology 2019, 37: 3005-3005. DOI: 10.1200/jco.2019.37.15_suppl.3005.
- Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Barrett J, Buck J, Demars N, Smith A, Miao J, Zhou Q, Gelb A, Cooper L. Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. Journal Of Clinical Oncology 2019, 37: 2053-2053. DOI: 10.1200/jco.2019.37.15_suppl.2053.
- Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Shao Y, Karlin-Neumann G, Polsky D, Chi A. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Journal Of Clinical Oncology 2019, 37: 2026-2026. DOI: 10.1200/jco.2019.37.15_suppl.2026.
- Yu S, Patel A, Crispino S, Utate M, Kurz S. Longer Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups (S30.007). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s30.007.
- Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.
- Kurz S, Liechty B, Kelly S, Vasudevaraja V, Bledea R, Wu P, Serrano J, Katz L, Silverman J, Pacione D, Golfinos J, Chi A, Snuderl M. GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES. Neuro-Oncology 2018, 20: vi106-vi106. PMCID: PMC6216611, DOI: 10.1093/neuonc/noy148.442.
- Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.
- Kurz S, Kelly S, Vasudevaraja V, Liechty B, Bledea R, Wu P, Serrano J, Katz L, Silverman J, Pacione D, Russel S, Sen C, Golfinos J, Chi A, Snuderl M. Characterization of clinically aggressive meningiomas by mutational signatures associated with DNA mismatch repair and aging. Journal Of Clinical Oncology 2018, 36: e14044-e14044. DOI: 10.1200/jco.2018.36.15_suppl.e14044.
- Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.
Departments and Programs
Locations
Chênevert Family Brain Tumor Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 8
New Haven, CT 06511
- Chênevert Family Brain Tumor CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
Biography
Sylvia Kurz, MD, PhD, specializes in neuro-oncology and provides care for patients with brain tumors as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center.
An associate professor of neurology at Yale School of Medicine, Dr. Kurz's research focuses on developing new therapies and improving existing treatment protocols for brain tumors.
Dr. Kurz earned her medical and doctoral degrees from Ludwig-Maximilians-University in Germany. She completed her residency at University Hospitals Case Medical Center and a fellowship in neuro-oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital.
Titles
- Associate Professor of Neurology, Neuro-Oncology
Education & Training
- Clinical FellowMassachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School (2017)
- Research FellowDana-Farber Cancer Institute Harvard Medical School (2016)
- ResidentUniversity Hospitals Case Medical Center, Case Western Reserve University (2014)
- PhDMax-Planck-Institute for Neurobiology and Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Molecular Medicine
- InternUniversity Hospitals Case Medical Center, Case Western Reserve University (2011)
- MDLudwig-Maximilians-University, School of Medicine
Languages Spoken
- English
- Deutsch (German)
Additional Information
Board Certifications
- United Council for Neurologic Subspecialties, Neuro-Oncology (2014, recertified: 2024)
Publications
- Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.
- Cloughesy T, Allen J, Arrillaga-Romany I, Barbaro M, Batchelor T, Butowski N, Cluster A, de Groot J, Graber J, Haggiagi A, Kilburn L, Kurz S, Melemed A, Ramage S, Salacz M, Shonka N, Sumrall A, Tarapore R, Taylor L, Wen P. CTNI-54. RESPONSE BY RANO2.0 CRITERIA IN ONC201 (DORDAVIPRONE)-TREATED PATIENTS WITH RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology 2024, 26: viii109-viii109. PMCID: PMC11552873, DOI: 10.1093/neuonc/noae165.0421.
- Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.
- Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.
- Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.
- Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek H, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE). Neuro-Oncology Practice 2024, 11: 336-346. PMID: 38737615, PMCID: PMC11085831, DOI: 10.1093/nop/npae002.
- Spieker M, Rapp M, Goebel S, Karger A, Rieger D, Grosse L, Bombach P, Kurz S, Hippler M, Tatagiba M, Sabel M, Tabatabai G, Renovanz M. NCOG-32. THE SPECIFIC PSYCHOSOCIAL BURDEN OF CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS - A PROSPECTIVE STUDY. Neuro-Oncology 2023, 25: v221-v221. PMCID: PMC10639804, DOI: 10.1093/neuonc/noad179.0845.
- Kurz S, Renovanz M, Rieger J, Bombach P, Grosse L, Rieger D, Hucker S, Hille H, Hippler M, Oener O, Ruhm K, Beha J, Malek H, Moeller Y, Bitzer M, Malek N, Tabatabai G. NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS. Neuro-Oncology 2023, 25: v220-v220. PMCID: PMC10639832, DOI: 10.1093/neuonc/noad179.0842.
- Kurz S, Stammberger A, Rosahl S, Abrey L, Albert N, von Baumgarten L, Gempt J, Grosu A, Leidgens V, McLean A, Renovanz M, Schwarzenberger J, Sevenich L, Purkart T, Combs S, Tabatabai G, Hegi M, Nowosielski M. Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative. Neuro-Oncology 2023, 25: 2302-2304. PMID: 37738478, PMCID: PMC10708925, DOI: 10.1093/neuonc/noad157.
- Spieker M, Rapp M, Rieger D, Bombach P, Kurz S, Tatagiba M, Sabel M, Tabatabai G, Renovanz M. P08.03.A CAREGIVERS OF ADULT NEURO-ONCOLOGICAL PATIENTS: UNMET NEEDS AND RELEVANT PROBLEMS - A PROSPECTIVE STUDY. Neuro-Oncology 2023, 25: ii55-ii56. PMCID: PMC10489286, DOI: 10.1093/neuonc/noad137.178.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology 2023, 101: e1741-e1746. PMID: 37527941, PMCID: PMC10624483, DOI: 10.1212/wnl.0000000000207670.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma. Journal Of Clinical Oncology 2023, 41: 2079-2079. DOI: 10.1200/jco.2023.41.16_suppl.2079.
- Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.
- Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.
- de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, O'Brien B, Sloan A, Chiang V, Tatter S, Mohammadi A, Placantonakis D, Strowd R, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope K, Campian J, Kurz S, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt E. SURG-23. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA. Neuro-Oncology 2022, 24: vii256-vii257. PMCID: PMC9660753, DOI: 10.1093/neuonc/noac209.989.
- Kurz S, Zan E, Cordova C, Barbaro M, Troxel A, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY. Neuro-Oncology 2022, 24: vii85-vii85. DOI: 10.1093/neuonc/noac209.322.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Forsyth P, Mandel J, Khagi S, Aiken R, Walbert T, Lieberman F, Portnow J, Battiste J, Gillespie E, Lowy I, Skolnik J. Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Journal Of Clinical Oncology 2022, 40: 2004-2004. DOI: 10.1200/jco.2022.40.16_suppl.2004.
- Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.
- Strowd R, Dunbar E, Gan H, Kurz S, Jordan J, Mandel J, Mohile N, Nevel K, Taylor J, Ullrich N, Welch M, Wasilewski A, Mrugala M. Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice 2022, 9: 91-104. PMID: 35371525, PMCID: PMC8965064, DOI: 10.1093/nop/npac002.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.
- Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.
- Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Forsyth P, Mandell J, Khagi S, Aiken R, Walbert T, Lieberman F, Portnow J, Batiste J, Carroll N, Sylvester A, Campbell P, Lowy I, Dolgoter A, Boyer J, Kraynyak K, Morrow M, McMullan T, Weiner D, Skolnik J. LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2020, 22: ii237-ii237. PMCID: PMC7678727, DOI: 10.1093/neuonc/noaa215.988.
- Liu E, Yu S, Sulman E, Kurz S. EPID-15. RACIAL AND SOCIOECONOMIC DISPARITIES DIFFERENTIALLY AFFECT OVERALL AND CAUSE-SPECIFIC SURVIVAL IN GLIOBLASTOMA. Neuro-Oncology 2020, 22: ii81-ii81. PMCID: PMC7651412, DOI: 10.1093/neuonc/noaa215.333.
- Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, de Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Taylor L, Graber J, Kilburn L, Dixit K, Lu G, Allen J, Batchelor T, Lassman A, Wen P. CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology 2020, 22: ii50-ii51. PMCID: PMC7651099, DOI: 10.1093/neuonc/noaa215.204.
- Lukas R, Chiocca E, Bush N, Landolfi J, Cavaliere R, Yu J, Kurz S, Demars N, Buck J, Hadar N, Miao J, Loewy J, Wang Y, Gelb A, Cooper L. CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology 2020, 22: ii39-ii39. PMCID: PMC7650356, DOI: 10.1093/neuonc/noaa215.162.
- Kurz S, Zan E, Gurewitz J, Cordova C, Troxel A, Sawaged Z, Sevillano-Torres H, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA. Neuro-Oncology 2020, 22: ii54-ii55. PMCID: PMC7651467, DOI: 10.1093/neuonc/noaa215.219.
- Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.
- Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.
- Cordova C, Kurz S. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports 2020, 22: 84. PMID: 32617743, DOI: 10.1007/s11912-020-00937-4.
- Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.
- Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.
- Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Karlin-Neumann G, Polsky D, Chi A. Abstract A65: Longitudinal detection of TERT-mutant plasma cell-free circulating tumor DNA in newly diagnosed glioblastoma patients. Clinical Cancer Research 2020, 26: a65-a65. DOI: 10.1158/1557-3265.liqbiop20-a65.
- Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.
- Kawakibi A, Tarapore R, Gardner S, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, De Groot J, Mehta M, Odia Y, Hall M, Cloughesy T, Ellingson B, Umemura Y, Allen J, Koschmann C. Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. Journal Of Clinical Oncology 2020, 38: 3617-3617. DOI: 10.1200/jco.2020.38.15_suppl.3617.
- Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, De Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Lu G, Oster W, Allen J, Batchelor T, Lassman A, Wen P. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal Of Clinical Oncology 2020, 38: 3615-3615. DOI: 10.1200/jco.2020.38.15_suppl.3615.
- Lukas R, Kurz S, Yu J, Landolfi J, Rao G, Amidei C, Buck J, Hadar N, Estupinan T, Miao J, Loewy J, Wang Y, Demars N, Gelb A, Cooper L. Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone. Journal Of Clinical Oncology 2020, 38: 2564-2564. DOI: 10.1200/jco.2020.38.15_suppl.2564.
- Kurz S, Tarapore R, Odia Y, Butowski N, Koschmann C, Aguilera D, MacDonald T, Lu G, Allen J, Oster W, Mehta M, Chi A, Wen P. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. Journal Of Clinical Oncology 2020, 38: 2563-2563. DOI: 10.1200/jco.2020.38.15_suppl.2563.
- Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Carroll N, Bartra S, Campbell P, Bhatt K, Lowy I, Boyer J, Kraynyak K, Morrow M, McMullan T, Weiner D, Skolnik J. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal Of Clinical Oncology 2020, 38: 2514-2514. DOI: 10.1200/jco.2020.38.15_suppl.2514.
- Liu E, Kurz S, Ahn J, Sulman E. Prevalence and temporal trends of prescription drug use in cancer survivors: A population study, 2001 to 2016. Journal Of Clinical Oncology 2020, 38: 12023-12023. DOI: 10.1200/jco.2020.38.15_suppl.12023.
- Skolnik J, Reardon D, Brem S, Desai A, Bagley S, Kurz S, de la Fuente M, Nagpal S, Welch M, Sacchetta B, Bartra S, Bredlau A, Lowy I, Kraynyak K, Morrow M, McMullan T, Boyer J. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM). Journal For ImmunoTherapy Of Cancer 2020, 8: a8. DOI: 10.1136/lba2019.12.
- Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.
- Mureb M, Jain R, Poisson L, Littig I, Neto L, Wu C, Ng V, Patel S, Patel S, Serrano J, Kurz S, Cahill D, Bendszus M, von Deimling A, Placantonakis D, Golfinos J, Kickingereder P, Snuderl M, Chi A. NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology 2019, 21: vi163-vi163. PMCID: PMC6847952, DOI: 10.1093/neuonc/noz175.681.
- Patel P, Li T, Chou J, Patel A, Crispino S, Utate M, Kurz S. HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS. Neuro-Oncology 2019, 21: vi118-vi118. PMCID: PMC6846933, DOI: 10.1093/neuonc/noz175.494.
- Li T, Patel P, Chou J, Patel A, Crispo S, Utate M, Kurz S. EPID-29. THE INFLUENCE OF SOCIOECONOMIC FACTORS AND CANCER CARE RECEIVED AT DIFFERENT FACILITIES ON OUTCOME IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi80-vi81. PMCID: PMC6847338, DOI: 10.1093/neuonc/noz175.329.
- Arrillaga-Romany I, Kurz S, Sumrall A, Butowski N, Harrison R, DeGroot J, Chi A, Sulman E, Shonka N, Umemura Y, Odia Y, Mehta M, Iwamoto F, Nghiemphu P, Cloughesy T, Tarapore R, Merdinger K, Oster W, Allen J, Batchelor T, Lassman A, Wen P. ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology 2019, 21: vi20-vi21. PMCID: PMC6847973, DOI: 10.1093/neuonc/noz175.077.
- Kurz S, Silverman J, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, Zagzag D, Snuderl M, Goldberg J, S A. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi9-vi10. PMCID: PMC6847193, DOI: 10.1093/neuonc/noz175.036.
- Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Buck J, Demars N, Smith A, Miao J, Zhou J, Wang Y, Gelb A, Cooper L. ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847372, DOI: 10.1093/neuonc/noz175.018.
- Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.
- Arrillaga I, Kurz S, Sumrall A, Butowski N, Harrison R, De Groot J, Shonka N, Lieberman F, Odia Y, Tarapore R, Merdinger K, Allen J, Oster W, Mehta M, Cloughesy T, Chi A, Lassman A, Batchelor T, Wen P. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal Of Clinical Oncology 2019, 37: 3005-3005. DOI: 10.1200/jco.2019.37.15_suppl.3005.
- Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Barrett J, Buck J, Demars N, Smith A, Miao J, Zhou Q, Gelb A, Cooper L. Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM. Journal Of Clinical Oncology 2019, 37: 2053-2053. DOI: 10.1200/jco.2019.37.15_suppl.2053.
- Cordova C, Syeda M, Corless B, Wiggins J, Patel A, Kurz S, Delara M, Sawaged Z, Utate M, Placantonakis D, Golfinos J, Schafrick J, Silverman J, Jain R, Snuderl M, Zagzag D, Shao Y, Karlin-Neumann G, Polsky D, Chi A. Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays. Journal Of Clinical Oncology 2019, 37: 2026-2026. DOI: 10.1200/jco.2019.37.15_suppl.2026.
- Yu S, Patel A, Crispino S, Utate M, Kurz S. Longer Median Overall Survival in Glioblastoma Patients from Racial and Ethnical Minority Groups (S30.007). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s30.007.
- Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.
- Kurz S, Liechty B, Kelly S, Vasudevaraja V, Bledea R, Wu P, Serrano J, Katz L, Silverman J, Pacione D, Golfinos J, Chi A, Snuderl M. GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES. Neuro-Oncology 2018, 20: vi106-vi106. PMCID: PMC6216611, DOI: 10.1093/neuonc/noy148.442.
- Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.
- Kurz S, Kelly S, Vasudevaraja V, Liechty B, Bledea R, Wu P, Serrano J, Katz L, Silverman J, Pacione D, Russel S, Sen C, Golfinos J, Chi A, Snuderl M. Characterization of clinically aggressive meningiomas by mutational signatures associated with DNA mismatch repair and aging. Journal Of Clinical Oncology 2018, 36: e14044-e14044. DOI: 10.1200/jco.2018.36.15_suppl.e14044.
- Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.
Departments and Programs
Locations
Chênevert Family Brain Tumor Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 8
New Haven, CT 06511
- Chênevert Family Brain Tumor CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
Chênevert Family Brain Tumor Center
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 8
New Haven, CT 06511
- Chênevert Family Brain Tumor CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511